Breaking Barriers, Enhancing Outcomes
Next-Generation Targeted Radioligand Therapies for Cancer Patients
AlphaGen Therapeutics is pioneering the discovery, development and commercialization of innovative radioligand therapies (RLTs). With our cutting-edge technology platform, we are developing a new class of alpha RLTs for patients in China and around the world.
AlphaGen has secured a next-generation Pb-212 isolation technology that is strongly positioned to build a leading radiopharmaceutical platform in China.
Improved therapeutic window as a result of decreased off-target radiation in healthy tissue
Abundant raw material supply from existing stockpiles
Lower radiation activity enabling broader hospital and market access
With our global expertise and innovative capabilities, we are committed to developing highly differentiated alpha and beta radioligand therapies, aiming to improve the effectiveness of cancer treatment and enhance the quality of life for patients globally.
Our goal is to accelerate the development of and improve patient access to innovative radioligand therapies. To achieve this purpose, we partner with leading biotech / pharmaceutical companies, renowned academic research institutions, and health systems globally.
Realizing China’s market potential by tapping into our deep understanding of the domestic landscape
Enhancing global pipelines to improve patient outcomes around the world with our novel therapies
Co-developing medicines with our cutting-edge technology
We are excited by the work we do and welcome others who are passionate about driving innovation in China and around the world to join us. AlphaGen is dedicated to advancing the radiopharmaceutical field and revolutionizing cancer treatments.
We are looking for highly qualified and motivated individuals who are excited to bring life-improving medicines to cancer patients.
At AlphaGen, we aim to navigate a host of multidisciplinary challenges—discover and develop compelling R&D programs; work closely with local and global partners to bring technologies into China and around the world; and bring a new class of life-changing therapies to an untapped market.
Join us and our team of scientists and industry leaders who have diverse perspectives and are passionate about advancing the next generation of radiopharmaceuticals and alpha radioligand therapies, and ultimately, transforming people’s lives.